
Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close. Contributing meaningfully to the stock's rise so far this year was the firm’s Q4 2024 earnings report on Feb. 6. Sales of the company’s GLP-1 drugs are still red-hot.
But does this mean a rally in Eli Lilly is likely to continue? Below, I’ll discuss essential points from the earnings report and management commentary. I’ll then provide an outlook on the company's shares.